The (medical) future is here, just unevenly distributed.
The (medical) future is here, just unevenly distributed
The lessons from Glybera, the first gene therapy to be sold in Europe, still loom large. It cures a genetic condition that causes a dangerously high amount of fat to build up in the blood system. Priced at $1m, the product has only been bought once since 2012 and stands out as a commercial disaster. Economist